tiprankstipranks
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

ANTX Stock Latest News

AN2 Therapeutics, Inc.: Hold Rating Amid Strategic Shift and Financial Resilience
RatingsAN2 Therapeutics, Inc.: Hold Rating Amid Strategic Shift and Financial Resilience
8d ago
ANTX
AN2 Therapeutics reports Q1 EPS (35c) vs. (56c) last year
PremiumThe Fly
AN2 Therapeutics reports Q1 EPS (35c) vs. (56c) last year
10d ago
ANTX
AN2 Therapeutics price target lowered to $2 from $5 at Citizens JMP
PremiumThe Fly
AN2 Therapeutics price target lowered to $2 from $5 at Citizens JMP
18d ago
ANTX
AN2 Therapeutics Faces Setback in Phase 3 Study
PremiumCompany Announcements
AN2 Therapeutics Faces Setback in Phase 3 Study
22d ago
8K
ANTX
AN2 Therapeutics reports data fro previously terminated EBO-301 Study
PremiumThe Fly
AN2 Therapeutics reports data fro previously terminated EBO-301 Study
22d ago
ANTX
AN2 Therapeutics, Inc.: Hold Rating Amid Mixed Clinical Results and Strong Financial Position
PremiumRatingsAN2 Therapeutics, Inc.: Hold Rating Amid Mixed Clinical Results and Strong Financial Position
1M ago
ANTX
AN2 Therapeutics Reports 2024 Financials and Pipeline Progress
Premium
Company Announcements
AN2 Therapeutics Reports 2024 Financials and Pipeline Progress
2M ago
ANTX
AN2 Therapeutics, Inc.: Hold Rating Amid Mixed Clinical Results and Stable Financial Outlook
Premium
Ratings
AN2 Therapeutics, Inc.: Hold Rating Amid Mixed Clinical Results and Stable Financial Outlook
2M ago
ANTX
AN2 Therapeutics, Inc.: Promising Future with Strong Financial Health and Strategic Advancements
PremiumRatings
AN2 Therapeutics, Inc.: Promising Future with Strong Financial Health and Strategic Advancements
2M ago
ANTX
AN2 Therapeutics reports Q4 EPS (25c) vs (57c) last year
PremiumThe Fly
AN2 Therapeutics reports Q4 EPS (25c) vs (57c) last year
2M ago
ANTX
ANTX Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
ANTX Upcoming Earnings Report: What to Expect?
2M ago
ANTX
Optimistic Buy Rating for AN2 Therapeutics Driven by Strong Phase 2 Results and Strategic FDA Alignment
PremiumRatings
Optimistic Buy Rating for AN2 Therapeutics Driven by Strong Phase 2 Results and Strategic FDA Alignment
3M ago
ANTX
AN2 Therapeutics submits amended EBO-301 trial statistical analysis plan to FDA
PremiumThe FlyAN2 Therapeutics submits amended EBO-301 trial statistical analysis plan to FDA
3M ago
ANTX
Citizens JMP healthcare analysts hold an analyst/industry conference call
Premium
The Fly
Citizens JMP healthcare analysts hold an analyst/industry conference call
3M ago
ANTX
INSM
JMP Securities healthcare analysts hold an analyst/industry conference call
Premium
The Fly
JMP Securities healthcare analysts hold an analyst/industry conference call
4M ago
ANTX
INSM
AN2 Therapeutics downgraded to Hold from Buy at TD Cowen
PremiumThe Fly
AN2 Therapeutics downgraded to Hold from Buy at TD Cowen
6M ago
ANTX
AN2 Therapeutics reports Q3 EPS (43c), consensus (38c)
PremiumThe Fly
AN2 Therapeutics reports Q3 EPS (43c), consensus (38c)
6M ago
ANTX
AN2 Therapeutics Promotes Joshua Eizen to Key Roles
PremiumCompany Announcements
AN2 Therapeutics Promotes Joshua Eizen to Key Roles
7M ago
8K
ANTX
AN2 Therapeutics gets continuation grant to discover novel boron based therapies
PremiumThe Fly
AN2 Therapeutics gets continuation grant to discover novel boron based therapies
7M ago
ANTX
AN2 Therapeutics adopts limited duration stockholder rights plan
PremiumThe FlyAN2 Therapeutics adopts limited duration stockholder rights plan
9M ago
ANTX
AN2 Therapeutics reports Q2 EPS (48c), consensus (59c)
Premium
The Fly
AN2 Therapeutics reports Q2 EPS (48c), consensus (59c)
9M ago
ANTX
Morning Movers: Iteris skyrockets following take-private agreement
Premium
The Fly
Morning Movers: Iteris skyrockets following take-private agreement
10M ago
CGC
ITI

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >